Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 32,900 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $190.46, for a total transaction of $6,266,134.00. Following the transaction, the chief marketing officer now owns 291,667 shares of the company’s stock, valued at $55,550,896.82. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Jane Huang also recently made the following trade(s):
- On Tuesday, September 3rd, Jane Huang sold 2,862 shares of Beigene stock. The shares were sold at an average price of $144.45, for a total transaction of $413,415.90.
- On Monday, August 12th, Jane Huang sold 2,500 shares of Beigene stock. The shares were sold at an average price of $134.74, for a total transaction of $336,850.00.
NASDAQ:BGNE traded up $1.53 during midday trading on Thursday, hitting $191.12. The company had a trading volume of 598 shares, compared to its average volume of 415,476. Beigene Ltd has a 52-week low of $108.00 and a 52-week high of $193.90. The stock’s fifty day moving average price is $135.93 and its 200-day moving average price is $130.62. The company has a market capitalization of $9.08 billion, a PE ratio of -15.69 and a beta of 1.00. The company has a quick ratio of 6.28, a current ratio of 6.46 and a debt-to-equity ratio of 0.15.
Beigene (NASDAQ:BGNE) last announced its earnings results on Thursday, August 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.01) by $1.58. Beigene had a negative net margin of 153.32% and a negative return on equity of 38.41%. The company had revenue of $243.35 million during the quarter, compared to analyst estimates of $65.58 million. During the same period in the previous year, the business earned ($2.92) earnings per share. The firm’s quarterly revenue was up 360.8% compared to the same quarter last year. As a group, research analysts forecast that Beigene Ltd will post -11.49 earnings per share for the current year.
Large investors have recently made changes to their positions in the stock. Capital Investment Advisory Services LLC purchased a new position in Beigene in the second quarter worth $26,000. Ladenburg Thalmann Financial Services Inc. grew its position in Beigene by 24.8% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 443 shares of the company’s stock worth $55,000 after acquiring an additional 88 shares in the last quarter. Riverhead Capital Management LLC grew its position in Beigene by 28.6% in the second quarter. Riverhead Capital Management LLC now owns 450 shares of the company’s stock worth $56,000 after acquiring an additional 100 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Beigene in the third quarter worth $58,000. Finally, Marshall Wace North America L.P. purchased a new position in Beigene in the first quarter worth $76,000.
BGNE has been the subject of a number of recent analyst reports. Maxim Group boosted their price target on shares of Beigene from $170.00 to $210.00 and gave the company a “buy” rating in a research report on Monday. Zacks Investment Research lowered shares of Beigene from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Guggenheim set a $205.00 price target on shares of Beigene and gave the company a “buy” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. set a $215.00 target price on shares of Beigene and gave the stock a “buy” rating in a research report on Monday. Finally, Cowen reiterated a “buy” rating and issued a $170.00 target price on shares of Beigene in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. Beigene currently has a consensus rating of “Buy” and an average price target of $192.67.
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Read More: Equity Income
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.